sorafenib has been researched along with THZ531 in 1 studies
| Studies (sorafenib) | Trials (sorafenib) | Recent Studies (post-2010) (sorafenib) | Studies (THZ531) | Trials (THZ531) | Recent Studies (post-2010) (THZ531) |
|---|---|---|---|---|---|
| 6,520 | 730 | 5,251 | 19 | 0 | 18 |
| Protein | Taxonomy | sorafenib (IC50) | THZ531 (IC50) |
|---|---|---|---|
| Cyclin-T1 | Homo sapiens (human) | 0.5135 | |
| Cyclin-K | Homo sapiens (human) | 0.2656 | |
| Cyclin-A2 | Homo sapiens (human) | 1.3 | |
| Cyclin-dependent kinase 2 | Homo sapiens (human) | 1.3 | |
| Cyclin-dependent kinase 7 | Homo sapiens (human) | 4.4025 | |
| Cyclin-dependent kinase 9 | Homo sapiens (human) | 0.5135 | |
| Cyclin-H | Homo sapiens (human) | 5.8173 | |
| CDK-activating kinase assembly factor MAT1 | Homo sapiens (human) | 8.5 | |
| Cyclin-dependent kinase 13 | Homo sapiens (human) | 0.265 | |
| Cyclin-dependent kinase 12 | Homo sapiens (human) | 2.3247 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 1 (100.00) | 2.80 |
| Authors | Studies |
|---|---|
| Beijersbergen, RL; Bernards, R; du Chatinier, A; Gao, D; Jin, G; Jin, H; Lieftink, C; Qin, W; Wang, C; Wang, H | 1 |
1 other study(ies) available for sorafenib and THZ531
| Article | Year |
|---|---|
CDK12 inhibition mediates DNA damage and is synergistic with sorafenib treatment in hepatocellular carcinoma.
Topics: Anilides; Antineoplastic Agents; Carcinoma, Hepatocellular; Cell Culture Techniques; Cell Line, Tumor; Cyclin-Dependent Kinases; Humans; Liver Neoplasms; Pyrimidines; Sorafenib | 2020 |